Evidence map›Paper›PMID 39696317›Full record

ArticleBMC health services research2024

Feasibility of a Pharmabuddy Care Service for patients with Parkinson's disease.

C C M Stuijt, F Karapinar-Çarkit, C van de Steeg-van Gompel, T van Laar, B J F van den Bemt, M Heringa

Abstract read
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

C C M StuijtCenter of Excellence On Parkinson's Disease [Punt Voor Parkinson], Schaaksport 100, Groningen, the Netherlands. c.c.m.stuijt@umcg.nl.ORCID http://orcid.org/0000-0002-5514-7195
F Karapinar-ÇarkitDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, the Netherlands.ORCID http://orcid.org/0000-0002-3077-9663
C van de Steeg-van GompelSIR Institute for Pharmacy Practice and Policy, Leiden, the Netherlands.
T van LaarCenter of Excellence On Parkinson's Disease [Punt Voor Parkinson], Schaaksport 100, Groningen, the Netherlands.
B J F van den BemtDepartment of Pharmacy, Sint Maartenskliniek, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-8560-9514
M HeringaSIR Institute for Pharmacy Practice and Policy, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPharmaceutical care for patients with Parkinson's disease (PD) is complex. Specialized pharmaceutical care provided by a dedicated pharmacy team member (pharmabuddy) for these patients may reduce medication-related problems. The feasibility of this service for PD patients is unknown.

objectiveTo evaluate the feasibility of a Pharmabuddy Care Service (PCS) for PD patients in primary care pharmacies.

methodsPharmabuddies who offered PCS were invited to fill in a questionnaire to evaluate the feasibility of PCS. Patients received a patient questionnaire and were invited for an interview. Patient records provided information on medication-related problems and interventions. Feasibility was evaluated conform four domains of Bowen's Framework. First, acceptability included patients' satisfaction ratings and experiences, Pharmabuddy impression on start and continuation of the service. Second, demand included use by patients and provision by pharmabuddies. Third, implementation/practicality: implementation indicators and barriers and facilitators from patient- and pharmabuddy perspective and fourth limited efficacy: effect of the PCS on PD symptoms, medication related problems identified and interventions from patient records.

resultsTwenty-three (59%) patients completed the questionnaire, 9 were interviewed, 12 (67%) pharmabuddies responded. Acceptability was high among patients (mean 9.5 (SD 1.3) out of 10), 6 (50%) pharmacies (still) provided PCS. Demand: 56% of patients had 1-2 contact moments, 28% two or more. Ten pharmacies provided up to 14 patients per pharmacy with PCS, one up to 24. Implementation/practicality: important barriers were time constraints and perception of other healthcare professionals. Positive reactions from patients encouraged pharmabuddies to carry out their PCS-activities. Patients were positive about pharmabuddy's listening competency while knowledge could be improved. Limited efficacy: from patient records, 89 interventions were made in response to 93 (median 3 per patient (range 1-16)) medication related problems or questions, with 20 (87%) patients reporting a positive effect from their interaction with a pharmabuddy.

conclusionThis study shows PCS is highly appreciated by responding patients and can be feasible for primary care pharmacies. Several implementation issues are still present. Future studies should focus on quantifiable effects of PCS services as well as resource and perception hurdles.

Indexed as

Feasibility StudiesParkinson DiseaseAgedAged, 80 and overFemaleHumansMaleMiddle AgedPatient SatisfactionPrimary Health CareSurveys and QuestionnairesSpecialized pharmaceutical care, Parkinson's disease, Implementation & education

Identifiers

PMID39696317
PMCPMC11654004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.